An independent data safety monitoring board told OncoMed Pharmaceuticals Inc. (Nasdaq: OMED) that its pancreatic cancer treatment tarextumab was not improving survival sending the stock price plummeting $7.50 to $10.07.
OncoMed's tarextumab ineffective
January 25, 2016 at 12:38 PM EST
